EE05318B1 - Geelkompositsioon ja kompositsiooni transskrotaalne kasutamine hpogonadismi raviks - Google Patents

Geelkompositsioon ja kompositsiooni transskrotaalne kasutamine hpogonadismi raviks

Info

Publication number
EE05318B1
EE05318B1 EEP200300305A EEP200300305A EE05318B1 EE 05318 B1 EE05318 B1 EE 05318B1 EE P200300305 A EEP200300305 A EE P200300305A EE P200300305 A EEP200300305 A EE P200300305A EE 05318 B1 EE05318 B1 EE 05318B1
Authority
EE
Estonia
Prior art keywords
composition
treatment
transcrotal
pogonadism
gel
Prior art date
Application number
EEP200300305A
Other languages
English (en)
Estonian (et)
Inventor
Schulze Bernd
Nieschlag Eberhard
Original Assignee
Dr. August Wolff Gmbh & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. August Wolff Gmbh & Co. filed Critical Dr. August Wolff Gmbh & Co.
Publication of EE200300305A publication Critical patent/EE200300305A/xx
Publication of EE05318B1 publication Critical patent/EE05318B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
  • Cosmetics (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
EEP200300305A 2000-12-22 2001-12-20 Geelkompositsioon ja kompositsiooni transskrotaalne kasutamine hpogonadismi raviks EE05318B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10064205 2000-12-22
PCT/EP2001/015123 WO2002051421A2 (de) 2000-12-22 2001-12-20 Gelzusammensetzung und transskrotale applikation einer zusammensetzung zur behandlung von hypogonadismus

Publications (2)

Publication Number Publication Date
EE200300305A EE200300305A (et) 2003-12-15
EE05318B1 true EE05318B1 (et) 2010-08-16

Family

ID=7668398

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300305A EE05318B1 (et) 2000-12-22 2001-12-20 Geelkompositsioon ja kompositsiooni transskrotaalne kasutamine hpogonadismi raviks

Country Status (17)

Country Link
US (2) US20040044086A1 (cs)
EP (1) EP1347764B1 (cs)
AT (1) ATE356626T1 (cs)
CA (1) CA2432534C (cs)
CY (1) CY1106595T1 (cs)
CZ (1) CZ20031761A3 (cs)
DE (2) DE50112206D1 (cs)
DK (1) DK1347764T3 (cs)
EE (1) EE05318B1 (cs)
ES (1) ES2283446T3 (cs)
HR (1) HRP20030510A2 (cs)
HU (1) HUP0600234A3 (cs)
PL (1) PL206702B1 (cs)
PT (1) PT1347764E (cs)
SI (1) SI1347764T1 (cs)
SK (1) SK7932003A3 (cs)
WO (1) WO2002051421A2 (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
JP2008512425A (ja) * 2004-09-09 2008-04-24 ラボラトワール ブザン アンテルナスィヨナル 透過促進剤としてのプロピレングリコールを含むテストステロンゲル
EP1634583A1 (en) 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
RS52671B (sr) 2005-10-12 2013-06-28 Unimed Pharmaceuticals Llc Poboljšani gel testosterona i postupak korišćenja
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3860712A (en) * 1973-04-16 1975-01-14 Sterling Drug Inc Composition and method for treatment of acne or seborrhea
CA1165240A (en) * 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
CA1249968A (en) * 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
DK3994A (da) * 1994-01-10 1995-07-11 Frank Nielsen CDopbevaringssystem hvor CDcoverne monteres på en skinne
EP0952833A1 (de) * 1996-05-02 1999-11-03 Azupharma GmbH Topische penile androgen-applikation zur behandlung der erektilen dysfunktion
IL127189A0 (en) * 1996-05-22 1999-09-22 Diversified Pharmaceuticals In Compositions methods and devices for the transdermal delivery of drugs
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
CA2309688C (en) * 1997-11-10 2007-04-24 Cellegy Pharmaceuticals, Inc. Penetration enhancing and irritation reducing systems
DE19803193C1 (de) * 1998-01-28 1999-07-15 August Wolff Gmbh & Co Arzneim Pharmazeutische Zusammensetzung mit Lecithin und alpha-Bisabolol als Penetrationsbeschleuniger
CA2418135C (en) * 2000-08-03 2011-09-20 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
EP1317921B1 (fr) * 2001-12-07 2009-08-19 Besins International Belgique Composition pharmaceutique sous forme de gel ou de solution à base de dihydrotestostérone, son procédé de préparation et ses utilisations
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof

Also Published As

Publication number Publication date
ATE356626T1 (de) 2007-04-15
HRP20030510A2 (en) 2005-04-30
SK7932003A3 (en) 2003-11-04
CZ20031761A3 (cs) 2004-01-14
HUP0600234A3 (en) 2011-04-28
PT1347764E (pt) 2007-06-01
DE50112206D1 (de) 2007-04-26
EP1347764A2 (de) 2003-10-01
HUP0600234A2 (en) 2006-07-28
WO2002051421A3 (de) 2002-11-07
CY1106595T1 (el) 2012-01-25
DE20121209U1 (de) 2002-06-20
US20100317631A1 (en) 2010-12-16
PL366101A1 (en) 2005-01-24
ES2283446T3 (es) 2007-11-01
DK1347764T3 (da) 2007-07-23
EE200300305A (et) 2003-12-15
SI1347764T1 (sl) 2007-06-30
EP1347764B1 (de) 2007-03-14
WO2002051421A2 (de) 2002-07-04
CA2432534A1 (en) 2002-07-04
PL206702B1 (pl) 2010-09-30
CA2432534C (en) 2009-09-22
US20040044086A1 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
BR0113670A (pt) Composição farmacêutica e método para tratar hipogonadismo
ATE363271T1 (de) Verfahren zur verbesserung der grösse und des aussehens einer wunde
KR20010012902A (ko) 피부 보호 조성물 및 피부 외관의 개선 방법
EE200300305A (et) Geelkompositsioon ja kompositsiooni transskrotaalne kasutamine hüpogonadismi raviks
BG106030A (en) Pharmaceutical composition
DK1144474T3 (da) Vandig reaktiv spartelmasse
PT1017659E (pt) Tetra-hidronaftalenos substituidos e compostos analogos
AP1424A (en) 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
GB9714274D0 (en) Pharmaceutical composition
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
ES2166549T3 (es) Procedimiento de preparacion de 17-esteres de 9alfa,21-dihalo-pregnan-11beta,17alfadiol-20-onas.
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
BR0016638B1 (pt) compostos anÁlogos de homopiperidilbenzimidazàis substituÍdos como relaxantes féndicos, processo para preparar os mesmos, composiÇço farmacÊutica e processo para preparÁ-la.
ATE229518T1 (de) Cis-3,4-chromanderivate zur vorbeugung oder behandlungvon oestrogenbezogenen krankheiten oder syndromen
ATE160573T1 (de) 1,3.5 (10) - estratriene derivate mit oraler wirkung
DK1335930T3 (da) Fremgangsmåde til fremstilling af 3-oxo-4-azasteroider
BR0011261B1 (pt) composiÇço oral compreendendo perlita, e, uso de perlita.
DE60226313D1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
ES2189206T3 (es) Beta-alcoxiacrilatos contra la malaria.
AP1691A (en) A pharmaceutical composition comprising therapeutically effective quantities of calcium channel blockers in combination with quinolines.
ATE514426T1 (de) Formulierungen zur verringerung oder eliminierung der toxizität von umwelthormonen mit ursodesoxycholsäure
SE0001631D0 (sv) New use
ATE397615T1 (de) 6-o-alkyl-2-nor-2-substituierte ketolidderivate
NO20012169D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
AU2001287673A1 (en) Novel trioxepan compounds

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20101220